Search results for "FDA"

Article Reporting Quality Metrics to FDA
Since the publication of FDA’s draft guidance, Request for Quality Metrics, Guidance for Industry (1), in July 2015, we have been debating how to best capture and report quality metrics in our organiz…

Article Prepare for an FDA Bioburden Inspection
Anastasia Lolas, former FDA Biologics License Application (BLA) reviewer and inspector focusing on microbiology, shares her expert tips.

Article Prepare for an FDA Bioburden Inspection
A best-practices response will not only help you be prepared for any upcoming FDA inspection, it may also yield valuable insights to help improve processes and procedures. Anastasia Lolas, former FDA

Article FDA Urged to Preserve Biosimilar Naming Conventions
In a letter to FDA, NCPDP cited operational problems with the implementation of a system other than the current INN system and stated concerns about what kind of impact that a change in system would h…

Resource FDA Guidance Documents
A searchable database of FDA guidance documents

Resource FDA’s Adverse Event Reporting System (AERS)
The FDA uses AERS to monitor for new adverse events and medication errors that might occur with these marketed products.

Resource FDA Acronyms and Abbreviations
A searchable database of FDA acronyms and abbreviations

Article A Look Ahead at BioPharma Manufacturing and Regulation
In October 2010, FDA issued a framework for advancing regulatory science for public health, which focused on the following: accelerating delivery of new medical treatments; improving pediatric and chi…

Article Driving Improved Access to Biosimilars
In a formal statement in December 2018 (2), former FDA commissioner Scott Gottlieb referred to insulin prices, which have increased nearly 600% between 2001 and 2015, with the average US list price ri…

Article Regulatory Challenges in the QbD Paradigm
It's no wonder that "Supply Chain Management," "Accountability in a Global Environment," "Foreign Inspections," and "International Compliance" were some of the key sessions at the 2011 PDA/ FDA Joint …

Previous PageNext Page